All In Biotech

NDA 211288 · Pfizer

Vizimpro

Dacomitinib · Oral

NovelPriority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Dec 18, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Sep 27, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

55

4 Phase 3, 4 recruiting

FAERS reports

749

692 serious, 330 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 23, 2026.

VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 )

Mechanism: Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). In vitro dacomitinib also inhibited the activity of DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations. Dacomitinib demonstrated dose-dependent inhibition of EGFR and HER2 autophosphorylation and tumor growth in mice bearing subcutaneously implanted human tumor xenografts driven by HER family targets including mutated EGFR. Dacomitinib also exhibited...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 27, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
  • VIZIMPRO · DACOMITINIB 30MG · TABLET, ORAL · Discontinued
  • VIZIMPRO · DACOMITINIB 45MG · TABLET, ORAL · Discontinued
  • VIZIMPRO · DACOMITINIB 15MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Dacomitinib" as an intervention, any sponsor and status, largest first.

All 55 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death238
  • diarrhoea121
  • rash115
  • neoplasm progression78
  • paronychia58
  • blood pressure increased47
  • malignant neoplasm progression45
  • pruritus36
  • off label use34
  • dyspnoea32
  • decreased appetite29
  • vomiting28

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201211
201314
20148
20153
20162
20171
20185
201950
202077
2021131
2022207
2023128
202455
202541
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jun 8, 2026

    Vizimpro, Tablet, 15 mg (NDC 0069-0197-30). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Jun 8, 2026

    Vizimpro, Tablet, 45 mg (NDC 0069-2299-30). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Jun 8, 2026

    Vizimpro, Tablet, 30 mg (NDC 0069-1198-30). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vizimpro (Dacomitinib)

2024 spending

$2.6M

Beneficiaries

37

163 claims

Per beneficiary

$70,021

$516.82 per unit

View as table
YearSpending
2020$2,488,810
2021$2,472,649
2022$2,379,396
2023$2,774,626
2024$2,590,793

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 76 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.